SNN: Smith & Nephew plc - Summary | Jitta

Smith & Nephew plc

NYSE:SNN

Price
$28.86
Loss Chance
50.9%
3.52JITTA SCORE
> 1,000%Over Jitta Line
Jitta Ranking
215 / 1,128
2,031 / 4,928
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (34)
Recent Business Performance (22)
Financial Strength (67)
Return to Shareholders (30)
Competitive Advantage (39)
Jitta Signs
Dividend PayoutEvery year
Interest Coverage RatioVery Good
Revenue and EarningRevenue decline from 2019-2022
Operating MarginInconsistent
Recent Business PerformanceEarning decline 21.86% in the last year
New Share IssuedMore than 50% in 5 years
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.52
> 1,000%
2.06
245.44%
Health Care Equipment
4.92
22.15%
5.37
16.66%
6.29
57.07%
COMPANY DESCRIPTION
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.